Off-Label Drug Coverage Bill Clears NJ Assembly Panel

Law360, New York (March 7, 2013, 4:55 PM EST) -- The New Jersey Assembly Appropriations Committee on Thursday approved legislation that would require health benefits plans that are offered to individuals and small employers to also cover certain off-label uses for drugs that are approved by the U.S. Food and Drug Administration.

In an 8-1 vote, the panel passed Assembly Bill A1830, which is aimed at giving chronically or terminally ill patients options to use certain drugs that are potentially beneficial in treating them even though those drugs might not be explicitly approved for such off-label...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.